Navamedic ASA today announced the Company's first quarter 2015 financial results. Navamedic's profitability improved significantly from last year's first quarter, while sales increased by 44 per cent.

Navamedic had sales of NOK 61.8 million in the first quarter, compared to NOK 42.9 million last year.

The Company's EBITDA for the quarter was NOK 4.2 million, compared to NOK 2.0 million the first quarter of 2014. Earnings before taxes for the first quarter this year ended at NOK 1.5 million, against NOK 0.2 million last year.

All of Navamedic's three segments - Pharma, Medical Nutrition and Consumer Care - experienced sales growth and improved profitability in the first quarter. Of the geographical markets, Finland was the growth winner with a tripling of sales in the first quarter.


For further information, please contact interim CEO Håkan Josephsson, telephone +46 706 742 533 or CFO Bjørn Lindholt, telephone +47 9300 6601.


Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 120 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).

distributed by